Switch to:
Also traded in: Argentina, Austria, Germany, Italy, Mexico, Netherlands, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Equity-to-Asset 0.47
PHG's Equity-to-Asset is ranked lower than
72% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. PHG: 0.47 )
Ranked among companies with meaningful Equity-to-Asset only.
PHG' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.19  Med: 0.45 Max: 0.61
Current: 0.47
0.19
0.61
Debt-to-Equity 0.42
PHG's Debt-to-Equity is ranked lower than
52% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.36 vs. PHG: 0.42 )
Ranked among companies with meaningful Debt-to-Equity only.
PHG' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.16  Med: 0.34 Max: 2.87
Current: 0.42
0.16
2.87
Debt-to-EBITDA 2.83
PHG's Debt-to-EBITDA is ranked lower than
65% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.77 vs. PHG: 2.83 )
Ranked among companies with meaningful Debt-to-EBITDA only.
PHG' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.26  Med: 2.04 Max: 3.73
Current: 2.83
1.26
3.73
Interest Coverage 7.02
PHG's Interest Coverage is ranked lower than
73% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.01 vs. PHG: 7.02 )
Ranked among companies with meaningful Interest Coverage only.
PHG' s Interest Coverage Range Over the Past 10 Years
Min: 0.24  Med: 1.77 Max: 7.02
Current: 7.02
0.24
7.02
Piotroski F-Score: 3
Altman Z-Score: 2.35
WACC vs ROIC
8.86%
9.74%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 9.33
PHG's Operating Margin % is ranked higher than
66% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.59 vs. PHG: 9.33 )
Ranked among companies with meaningful Operating Margin % only.
PHG' s Operating Margin % Range Over the Past 10 Years
Min: 1.35  Med: 4.05 Max: 9.33
Current: 9.33
1.35
9.33
Net Margin % 7.16
PHG's Net Margin % is ranked higher than
76% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.48 vs. PHG: 7.16 )
Ranked among companies with meaningful Net Margin % only.
PHG' s Net Margin % Range Over the Past 10 Years
Min: -6.96  Med: 2.83 Max: 9.32
Current: 7.16
-6.96
9.32
ROE % 13.50
PHG's ROE % is ranked higher than
81% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.75 vs. PHG: 13.50 )
Ranked among companies with meaningful ROE % only.
PHG' s ROE % Range Over the Past 10 Years
Min: -10.67  Med: 4.65 Max: 13.5
Current: 13.5
-10.67
13.5
ROA % 5.80
PHG's ROA % is ranked higher than
76% of the 262 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.54 vs. PHG: 5.80 )
Ranked among companies with meaningful ROA % only.
PHG' s ROA % Range Over the Past 10 Years
Min: -4.74  Med: 1.81 Max: 5.8
Current: 5.8
-4.74
5.8
ROC (Joel Greenblatt) % 59.87
PHG's ROC (Joel Greenblatt) % is ranked higher than
79% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.57 vs. PHG: 59.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PHG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -11.41  Med: 27.93 Max: 70.22
Current: 59.87
-11.41
70.22
3-Year Revenue Growth Rate -6.70
PHG's 3-Year Revenue Growth Rate is ranked lower than
74% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. PHG: -6.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PHG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -33.6  Med: -1.3 Max: 64.6
Current: -6.7
-33.6
64.6
3-Year EBITDA Growth Rate 13.30
PHG's 3-Year EBITDA Growth Rate is ranked higher than
61% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. PHG: 13.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PHG' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -34.3  Med: -2.3 Max: 91.6
Current: 13.3
-34.3
91.6
3-Year EPS without NRI Growth Rate 53.00
PHG's 3-Year EPS without NRI Growth Rate is ranked higher than
91% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. PHG: 53.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PHG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -38.4 Max: 211.3
Current: 53
0
211.3
GuruFocus has detected 3 Warning Signs with Royal Philips NV PHG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PHG's 30-Y Financials

Financials (Next Earnings Date: 2019-01-24 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2017

PHG Guru Trades in Q4 2017

Eaton Vance Worldwide Health Sciences Fund 357,605 sh (New)
Jim Simons 1,085,178 sh (+283.35%)
Dodge & Cox 21,700 sh (-1.59%)
NWQ Managers 2,147,721 sh (-7.71%)
HOTCHKIS & WILEY 10,096,052 sh (-0.31%)
» More
Q1 2018

PHG Guru Trades in Q1 2018

Dodge & Cox 21,700 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 357,605 sh (unchged)
NWQ Managers 275,150 sh (-87.19%)
HOTCHKIS & WILEY 9,890,224 sh (-2.04%)
Jim Simons 425,778 sh (-60.76%)
» More
Q2 2018

PHG Guru Trades in Q2 2018

Dodge & Cox 21,700 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 357,605 sh (unchged)
NWQ Managers Sold Out
HOTCHKIS & WILEY 3,081,822 sh (-68.84%)
Jim Simons 140,347 sh (-67.04%)
» More
Q3 2018

PHG Guru Trades in Q3 2018

Murray Stahl 4,607 sh (New)
Eaton Vance Worldwide Health Sciences Fund 357,605 sh (unchged)
Dodge & Cox 21,700 sh (unchged)
Jim Simons Sold Out
HOTCHKIS & WILEY 1,052,730 sh (-65.84%)
» More
» Details

Insider Trades

Latest Guru Trades with PHG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research  
Compare:NYSE:A, NYSE:IQV, TSE:6869, XSWX:LONN, NYSE:LH, NAS:IDXX, NYSE:DGX, XTER:SRT3, SZSE:300676, XPAR:BIM, XPAR:ERF, NYSE:PKI, NYSE:DHR, NYSE:BIO, NYSE:QGEN, NAS:DXCM, NAS:ICLR, NAS:EXAS, XTER:AFX, NAS:PRAH » details
Traded in other countries:PHG.Argentina, PHIA.Austria, PHI1.Germany, PHIA.Italy, PHIA.Mexico, PHIA.Netherlands, PHI.Switzerland, 0LNG.UK, RYLPF.USA,
Headquarter Location:Netherlands
Royal Philips NV is a health technology company. The company provides various services in the area of personal health, diagnosis and treatment, connected care and health informatics businesses, and health tech.

Philips is a diversified global manufacturer operating in two segments: health tech and personal health. About 60% of revenue comes from the health tech segment, which features imaging systems, ultrasound equipment, patient monitoring systems, and image-guided therapy solutions. Personal health products like domestic appliances, health and wellness, and personal care contribute the remainder of Philips' turnover. In 2016, Philips generated EUR 17.4 billion of sales and had 105,000 employees in over 100 countries.

Ratios

vs
industry
vs
history
PE Ratio 21.34
PHG's PE Ratio is ranked higher than
79% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.00 vs. PHG: 21.34 )
Ranked among companies with meaningful PE Ratio only.
PHG' s PE Ratio Range Over the Past 10 Years
Min: 3.5  Med: 23.51 Max: 471.5
Current: 21.34
3.5
471.5
Forward PE Ratio 17.79
PHG's Forward PE Ratio is ranked higher than
85% of the 40 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. PHG: 17.79 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 36.98
PHG's PE Ratio without NRI is ranked higher than
51% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.56 vs. PHG: 36.98 )
Ranked among companies with meaningful PE Ratio without NRI only.
PHG' s PE Ratio without NRI Range Over the Past 10 Years
Min: 3.27  Med: 35.34 Max: 579.52
Current: 36.98
3.27
579.52
Price-to-Owner-Earnings 52.04
PHG's Price-to-Owner-Earnings is ranked higher than
61% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.75 vs. PHG: 52.04 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PHG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.13  Med: 20.29 Max: 67.87
Current: 52.04
5.13
67.87
PB Ratio 2.64
PHG's PB Ratio is ranked higher than
73% of the 245 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.02 vs. PHG: 2.64 )
Ranked among companies with meaningful PB Ratio only.
PHG' s PB Ratio Range Over the Past 10 Years
Min: 0.64  Med: 1.78 Max: 3.14
Current: 2.64
0.64
3.14
PS Ratio 1.74
PHG's PS Ratio is ranked higher than
80% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.81 vs. PHG: 1.74 )
Ranked among companies with meaningful PS Ratio only.
PHG' s PS Ratio Range Over the Past 10 Years
Min: 0.43  Med: 1 Max: 2.1
Current: 1.74
0.43
2.1
EV-to-EBIT 19.04
PHG's EV-to-EBIT is ranked higher than
69% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.06 vs. PHG: 19.04 )
Ranked among companies with meaningful EV-to-EBIT only.
PHG' s EV-to-EBIT Range Over the Past 10 Years
Min: -2227.9  Med: 19.5 Max: 2029.3
Current: 19.04
-2227.9
2029.3
EV-to-EBITDA 19.04
PHG's EV-to-EBITDA is ranked higher than
56% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.75 vs. PHG: 19.04 )
Ranked among companies with meaningful EV-to-EBITDA only.
PHG' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.4  Med: 10.65 Max: 24.4
Current: 19.04
3.4
24.4
EV-to-Revenue 1.83
PHG's EV-to-Revenue is ranked higher than
81% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. PHG: 1.83 )
Ranked among companies with meaningful EV-to-Revenue only.
PHG' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.4  Med: 1 Max: 2.3
Current: 1.83
0.4
2.3
PEG Ratio 15.75
PHG's PEG Ratio is ranked lower than
85% of the 48 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.26 vs. PHG: 15.75 )
Ranked among companies with meaningful PEG Ratio only.
PHG' s PEG Ratio Range Over the Past 10 Years
Min: 0.78  Med: 3.47 Max: 156.19
Current: 15.75
0.78
156.19
Shiller PE Ratio 59.37
PHG's Shiller PE Ratio is ranked higher than
59% of the 39 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.49 vs. PHG: 59.37 )
Ranked among companies with meaningful Shiller PE Ratio only.
PHG' s Shiller PE Ratio Range Over the Past 10 Years
Min: 4.44  Med: 12.8 Max: 71.53
Current: 59.37
4.44
71.53
Current Ratio 1.27
PHG's Current Ratio is ranked lower than
74% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.58 vs. PHG: 1.27 )
Ranked among companies with meaningful Current Ratio only.
PHG' s Current Ratio Range Over the Past 10 Years
Min: 1.03  Med: 1.41 Max: 20.59
Current: 1.27
1.03
20.59
Quick Ratio 0.89
PHG's Quick Ratio is ranked lower than
78% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. PHG: 0.89 )
Ranked among companies with meaningful Quick Ratio only.
PHG' s Quick Ratio Range Over the Past 10 Years
Min: 0.64  Med: 0.96 Max: 12.79
Current: 0.89
0.64
12.79
Days Inventory 79.96
PHG's Days Inventory is ranked lower than
57% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.76 vs. PHG: 79.96 )
Ranked among companies with meaningful Days Inventory only.
PHG' s Days Inventory Range Over the Past 10 Years
Min: 68.15  Med: 96.68 Max: 131.91
Current: 79.96
68.15
131.91
Days Payable 69.08
PHG's Days Payable is ranked higher than
57% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. PHG: 69.08 )
Ranked among companies with meaningful Days Payable only.
PHG' s Days Payable Range Over the Past 10 Years
Min: 2.28  Med: 90.97 Max: 132.43
Current: 69.08
2.28
132.43

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.65
PHG's Dividend Yield % is ranked higher than
83% of the 121 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.81 vs. PHG: 2.65 )
Ranked among companies with meaningful Dividend Yield % only.
PHG' s Dividend Yield % Range Over the Past 10 Years
Min: 1.99  Med: 3.23 Max: 6.1
Current: 2.65
1.99
6.1
Dividend Payout Ratio 0.96
PHG's Dividend Payout Ratio is ranked lower than
83% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.32 vs. PHG: 0.96 )
Ranked among companies with meaningful Dividend Payout Ratio only.
PHG' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.45  Med: 0.94 Max: 5
Current: 0.96
0.45
5
Forward Dividend Yield % 2.66
PHG's Forward Dividend Yield % is ranked higher than
82% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. PHG: 2.66 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.85
PHG's 5-Year Yield-on-Cost % is ranked higher than
99% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. PHG: 2.85 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
PHG' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.14  Med: 3.48 Max: 6.57
Current: 2.85
2.14
6.57
3-Year Average Share Buyback Ratio -0.40
PHG's 3-Year Average Share Buyback Ratio is ranked higher than
79% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.90 vs. PHG: -0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PHG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -7.8  Med: 0.3 Max: 8.4
Current: -0.4
-7.8
8.4

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 128.52
PHG's Price-to-Tangible-Book is ranked lower than
95% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.46 vs. PHG: 128.52 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PHG' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.69  Med: 3.29 Max: 278.85
Current: 128.52
1.69
278.85
Price-to-Intrinsic-Value-Projected-FCF 2.56
PHG's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
51% of the 75 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. PHG: 2.56 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PHG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.48  Med: 1.7 Max: 18.45
Current: 2.56
0.48
18.45
Price-to-Median-PS-Value 1.76
PHG's Price-to-Median-PS-Value is ranked lower than
76% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. PHG: 1.76 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PHG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.08  Med: 1.05 Max: 7.29
Current: 1.76
0.08
7.29
Price-to-Graham-Number 14.73
PHG's Price-to-Graham-Number is ranked lower than
89% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.98 vs. PHG: 14.73 )
Ranked among companies with meaningful Price-to-Graham-Number only.
PHG' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.61  Med: 2.33 Max: 36.75
Current: 14.73
0.61
36.75
Earnings Yield (Greenblatt) % 5.23
PHG's Earnings Yield (Greenblatt) % is ranked higher than
86% of the 265 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.98 vs. PHG: 5.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PHG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2.9  Med: 4.7 Max: 20.4
Current: 5.23
-2.9
20.4
Forward Rate of Return (Yacktman) % -6.73
PHG's Forward Rate of Return (Yacktman) % is ranked lower than
86% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.45 vs. PHG: -6.73 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PHG' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -7.1  Med: 1.8 Max: 20.8
Current: -6.73
-7.1
20.8

More Statistics

Revenue (TTM) (Mil) $21,170.26
EPS (TTM) $ 1.82
Beta1.16
Volatility25.11%
52-Week Range $35.09 - 46.67
Shares Outstanding (Mil)907.25 (ADR)

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 20,836 21,781 22,544
EBIT (Mil $) 2,279 2,676 3,122
EBITDA (Mil $) 3,338 3,689 4,296
EPS ($) 1.35 1.86 2.22
EPS without NRI ($) 1.35 1.86 2.22
EPS Growth Rate
(Future 3Y To 5Y Estimate)
1.15%
Dividends per Share ($) 0.85 0.98 0.99

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAY
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}